| 2009 Milion € | 2008 Milion € | Change % | |
| Sales | 4,028.2 | 3,786.4 | 6.4 |
| Profit After Functional Expenses | 444.5 | 390.6 | 13.8 |
| Operating Income | 410.6 | 345.7 | 18.8 |
| Consolidated Annual Net Profit | 239.6 | 185.0 | 29.5 |
| Net Opertating Margin (after Taxes, %) |
5.9 | 4.9 | 20.4 |
| Investments in Property, Plant and Equipment and Intangible Assets | 454.8 | 471.0 | -3.4 |
| Depreciation of Property, Plant and Equipment and Intangible Assets | 208.6 | 197.8 | 5.4 |
| Equity Ratio (%) | 40.8 | 37.5 | 8.8 |
| Equity Ratio including Loans from Shareholders (%) | 41.8 | 38.5 | 8.6 |
| Personnel Expenditure | 1,424.9 | 1,340.5 | 6.3 |
| Number of Employees (as of Dec 31, 2009) | 39,504 | 38,462 | 2.6 |
Financial year 2009 - the facts in brief
Sales: 4,028.2 million (+ 6.4 percent)
Profit After Functional Expenses: 444.5 million (+ 13.8 percent)
Operating Income: 410.6 million (+ 18.8 percent)
Consolidated Annual Net Profit: 239.6 million (+ 29.5 percent)
Net Opertating Margin: 5.9 percent (+ 20.4 percent)
Investments in Property, Plant and Equipment and Intangible Assets: 454.8 million (- 3.4 percent)
Depreciation of Property, Plant and Equipment and Intangible Assets: 208.6 million (+ 5.4 percent)
Equity Ratio: 40.8 percent (+ 8.8 percent)
Equity Ratio including Loans from Shareholders: 41.8 percent (+ 8.6 percent)
Personnel Expenditure: 1,424.9 million (+ 6.3 percent)
Number of Employees (as of Dec 31, 2009): 39,504 (+ 2.6 percent)
The Hospital Care Division offers integrated therapy concepts of products and services for anaesthesia, intensive and acute care, infusion therapy and urology; annual sales of €1,903.8 million (+7.9%).
Sales of the Aesculap Division, system supplier in the surgical area, rose to €1,153.2 million (+5.0%)
Out Patient Market Division (OPM) offers concepts of comprehensive patient care for the segment of physicians in private practice as well as out-patient and stationary care. Annual sales of €525.8 million (+6.1 %).
B. Braun Avitum, active in the field of extracorporeal blood treatment and dialysis, provider of dialysis centers throughout Europe; sales of €420.5 million means an increase of 4.4 percent in comparison to the previous year.
